 |
|
Drug-Eluting Stents and In-Stent Restenosis
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: From a practical standpoint, detailing the logistics required to administer the 600-mg clopidogrel pretreatment 2 hours before intervention, as was done in the study by Dr Kastrati and colleagues,1 will be helpful, considering that in most centers patients with in-stent restenosis undergo ad hoc reintervention, and only complex cases are scheduled for staged procedures. In addition, it would be valuable to identify potential predictors of drug-eluting stent failure to provide early triage and, eventually, to divert patients to alternative techniques.2-4
In this regard, although lesion length was not an exclusion criterion, the baseline median lesion length in the study was only 12 mm, and median stent length was twice as long. Therefore, knowing the criteria used to select stent length and the results of stent use in long lesions would be of major interest. Likewise, studies using intravascular ultrasound have demonstrated that drug-eluting stent underexpansion is a . . . [Full Text of this Article]
Fernando Alfonso, MD, PhD, FESC
falf@secardiologia.es
Interventional Cardiology
Cardiovascular Institute
San Carlos University Hospital
Madrid, Spain
RELATED ARTICLES
Drug-Eluting Stents and In-Stent Restenosis—Reply
Adnan Kastrati and Albert Schömig
JAMA. 2005;293(15):1855-1856.
EXTRACT
| FULL TEXT
Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis: A Randomized Controlled Trial
Adnan Kastrati, Julinda Mehilli, Nicolas von Beckerath, Alban Dibra, Jörg Hausleiter, Jürgen Pache, Helmut Schühlen, Claus Schmitt, Josef Dirschinger, Albert Schömig, and for the ISAR-DESIRE Study Investigators
JAMA. 2005;293(2):165-171.
ABSTRACT
| FULL TEXT
|
